<DOC>
	<DOCNO>NCT00969046</DOCNO>
	<brief_summary>This study explore different administration schedule ( short versus prolonged infusion ) optimize safety efficacy profile EPO906A ( patupilone ) patient pretreated advanced colon cancer .</brief_summary>
	<brief_title>Dose-Escalation Study Advanced Colon Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Epothilone B</mesh_term>
	<criteria>1 . Histologically confirm , locally advanced , progressive metastatic colon cancer , 4 prior line prior chemotherapy , least one measurable lesion accord RECIST 2 . Age ≥ 18 year 3 . Life expectancy ≥ 12 week 4. WHO performance status 01 5 . Negative serum pregnancy test 6 . Adequate hepatic renal function hematological parameter 1 . Brain metastases 2 . Ileostomy colonostomy 3 . History pelvic radiotherapy 4 . Grade &gt; 1 diarrhea baseline Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Colon cancer</keyword>
	<keyword>MTD</keyword>
	<keyword>DLT</keyword>
	<keyword>EPO906</keyword>
	<keyword>patupilone</keyword>
</DOC>